Navigation Links
Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
Date:11/8/2010

GREENWICH, Conn., Nov. 8, 2010 /PRNewswire/ -- Mederi Therapeutics Inc announced today that it has received a CE Mark authorizing the European distribution and use of Mederi's second generation of the Stretta and Secca Systems. The Stretta System is for treatment of gastric reflux disease, commonly known as GERD, and the Secca System is for treatment of bowel control disorder, or BCD.  These latest systems include a streamlined user interface, significant improvements in ease of use, and are smaller, lighter, and highly portable.

"Mederi is very pleased to offer the Stretta system for the treatment GERD and the Secca system for treatment of BCD. Mederi has made a substantial capital investment which has resulted in numerous improvements to these novel technologies," stated Will Rutan, CEO and President of Mederi Therapeutics. "The Secca and Stretta systems are ultra-minimally invasive technologies that bridge a significant gap that exists between conservative therapies and invasive surgical options for GERD and BCD. Numerous clinical studies have shown Stretta and Secca to be effective therapeutic options."

The second generation Stretta and Secca devices were launched at UEGW 2010, the annual congress of the United European Gastroenterology Federation, which was held in Barcelona, Spain, October 23-27. "It was exciting to witness the overwhelming response to Stretta and Secca, resulting in numerous requests to purchase Mederi products at the recent European congress. As the only endoluminal therapies for GERD and BCD, the interest and demand for these novel technologies is extremely high," added Rutan. Concurrent with the EU launch activities, Mederi has engaged and trained a worldwide distribution network to drive demand and ensure safe and proper use of Stretta and Secca.

The CE Mark and ISO 13485 certification demonstrate Mederi's steadfast commitment to safety and quality.

Additional information is available at www.mederitherapeutics.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.Contact: Sheila DoyleManager of Communications and Marketing203 930 9980
'/>"/>

SOURCE Mederi Therapeutics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
4. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
5. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
6. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
7. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
9. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
10. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
11. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... BALTIMORE , Jan. 17, 2017 Paragon ... to provide product development services for a variety ... Diseases (NIAID) medical product development activities. The ... a contractor pool for task order awards up ... global leader in manufacturing and process development of ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
(Date:1/17/2017)... Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... been enrolled in a Phase 3 clinical trial comparing ... care (BSC) in the prevention of hepatic veno-occlusive disease ... cell transplant (HSCT) who are at high risk or ... clinical trial will be conducted across approximately 100 medical ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based ... Medical Center is an exciting addition to our provider network, and the addition ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... Livingston, NJ (PRWEB) , ... January 17, 2017 , ... ... services and financial planning assistance to communities throughout the region, is launching a charity ... , Heart disease is by far the deadliest killer in America, and is responsible ...
Breaking Medicine News(10 mins):